Advertisement

Topics

AbbVie’s Elagolix succeeds in second phase 3 uterine fibroid study

05:17 EDT 14 Mar 2018 | Pharmaceutical Business Review

AbbVie, along with Neurocrine Biosciences, announced that the Phase 3 ELARIS UF-II study (M12-817) of elagolix met its primary endpoint.

Original Article: AbbVie’s Elagolix succeeds in second phase 3 uterine fibroid study

NEXT ARTICLE

More From BioPortfolio on "AbbVie’s Elagolix succeeds in second phase 3 uterine fibroid study"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...